Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded to Buy Rating by Wall Street Zen

Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research note issued on Sunday.

Several other equities research analysts have also recently weighed in on ALNY. HC Wainwright reiterated a “buy” rating and issued a $570.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, October 10th. Oppenheimer reiterated an “outperform” rating and issued a $500.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday. Piper Sandler restated an “overweight” rating and set a $489.00 price objective (up from $449.00) on shares of Alnylam Pharmaceuticals in a research note on Friday. Bank of America upped their price objective on Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a research note on Wednesday, September 17th. Finally, JPMorgan Chase & Co. decreased their price objective on Alnylam Pharmaceuticals from $475.00 to $473.00 and set an “overweight” rating for the company in a research note on Monday, October 13th. Twenty-three research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $478.67.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY stock opened at $456.04 on Friday. Alnylam Pharmaceuticals has a twelve month low of $205.87 and a twelve month high of $495.55. The stock has a market capitalization of $59.78 billion, a price-to-earnings ratio of -184.63 and a beta of 0.36. The stock has a fifty day simple moving average of $460.19 and a two-hundred day simple moving average of $369.93. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $1.39 by $1.51. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.The business had revenue of $1.25 billion during the quarter, compared to analysts’ expectations of $943.37 million. During the same period in the prior year, the business earned ($0.50) EPS. The business’s revenue for the quarter was up 149.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, EVP Jeffrey V. Poulton sold 3,821 shares of the stock in a transaction dated Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $1,727,283.05. Following the completion of the sale, the executive vice president directly owned 54,052 shares in the company, valued at approximately $24,434,206.60. This trade represents a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Yvonne Greenstreet sold 8,924 shares of the stock in a transaction dated Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total value of $4,034,094.20. Following the completion of the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at approximately $29,568,138.45. This trade represents a 12.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 98,144 shares of company stock valued at $44,160,261 in the last 90 days. 1.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ALNY. Brighton Jones LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $243,000. Amalgamated Bank grew its holdings in Alnylam Pharmaceuticals by 4.3% during the first quarter. Amalgamated Bank now owns 8,853 shares of the biopharmaceutical company’s stock worth $2,390,000 after acquiring an additional 369 shares during the period. Principal Financial Group Inc. grew its holdings in Alnylam Pharmaceuticals by 234.4% during the first quarter. Principal Financial Group Inc. now owns 34,701 shares of the biopharmaceutical company’s stock worth $9,370,000 after acquiring an additional 24,323 shares during the period. OneDigital Investment Advisors LLC grew its holdings in Alnylam Pharmaceuticals by 15.8% during the first quarter. OneDigital Investment Advisors LLC now owns 1,211 shares of the biopharmaceutical company’s stock worth $327,000 after acquiring an additional 165 shares during the period. Finally, IFM Investors Pty Ltd grew its holdings in Alnylam Pharmaceuticals by 9.4% during the first quarter. IFM Investors Pty Ltd now owns 25,919 shares of the biopharmaceutical company’s stock worth $7,129,000 after acquiring an additional 2,219 shares during the period. 92.97% of the stock is owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.